glp-1 weight loss drug news today Serena Williams Is the Surprising New Face of Weight-Loss Drugs A new study is raising

Epac proteins: multi-purpose cAMP targets

Ethics declarations Ethical approval and consent to participate Not applicable

In 1990 Mojsov and colleagues also described the existence of a second biologically active form of GLP-1, labelled GLP-1 (7-36) amide, in the intestines (Mojsov, Kopczynski, Habener)

Key areas of concern for decision makers and executives include: Continued rapid rates of increased utilization: Treatment guideline recommendations to prefer GLP-1 agonists and GIP/GLP-1 dual agonists over other less expensive diabetic treatments Increase in physicians awareness of obesity as a disease Stronger trust in the long-term effects and safety of GLP-1 receptor agonists Unwavering demand by individuals seeking quick weight loss solutions Additional products seeking approval and entering the market: Over 50 products are currently in clinical development for obesity and/or T2D GLP-1 agonism is being studied in combination with other mechanisms of action including GIP agonism, glucagon agonism, amylin agonism, and PYY agonism Shortages of currently marketed drugs provide opportunity for additional products to successfully enter the marketplace Additional indications for these products are gaining approval: Clinical trials are ongoing for several indications beyond the currently approved obesity and/or T2D uses Examples of therapeutic applications currently under investigation include Parkinsons and Alzheimers diseases, smoking cessation, alcoholism, and MASH The GLP-1 agonist market is rapidly evolving with significant implications for payers

Combined activation of both receptors may act synergistically providing additive effects on glucose and body weight in comparison of GLP1 analogues alone

Switching between GLP-1 medications does happen in clinical practice, usually when a patient has reached a plateau, experienced intolerable side effects, or when insurance coverage changes